Five biologics to launch in vasculitis treatment market

The vasculitis treatment market in the U.S. and major European pharmaceutical markets is expected to expand in value over the next decade according to a new report. GlobalData’s report suggests that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis, including Bristol-Myers Squibb’s (BMS) Orencia, Johnson & Johnson’s Remicade, GlaxoSmithKline’s (GSK) Benlysta and Nucala, and Roche’s Actemra. Vasculitis is a condition that involves inflammation in the blood vessels and the condition occurs if your immune system attacks your blood vessels by mistake. There are many